AAV miR ATXN 2
Alternative Names: AAV-miR-ATXN2Latest Information Update: 18 Jan 2024
At a glance
- Originator AviadoBio
- Class Antidementias; MicroRNAs
- Mechanism of Action Ataxin-2 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 02 Jan 2024 Early research in Frontotemporal dementia in United Kingdom (Parenteral) (Aviadobio pipeline, January 2024)
- 02 Jan 2024 Research trials in Amyotrophic lateral sclerosis in United Kingdom prior to January 2024 (Parenteral) (Aviadobio pipeline, January 2024)